Metsera's experimental obesity drug showed significant weight loss and favorable tolerability in two mid-stage studies, the drug developer said on Monday. The injectable drug, MET-097i, led to a ...

Weight loss injections seem to be more popular, but "compounded" versions of these drugs can vary in how people access them.

Novo Nordisk (NVO) has cemented itself as the leader in the booming weight-loss drug market with blockbuster treatments like ...

Morgan Stanley downgraded Novo Nordisk to underweight from equal-weight saying it sees slowing growth of its lucrative GLP-1 ...

Eli Lilly’s (LLY) weight-loss medications may have benefits for people suffering from Alzheimer’s disease, according to new studies. Take advantage of TipRanks Premium at 55% off! Unlock powerful ...

Eli Lilly’s valuation has compressed significantly from last year’s highs, despite improving fundamentals. See why I rate LLY ...

The Cleveland Clinic found in a September report that individuals with a version of the gene Neurobeachin were more likely to ...

Novo Nordisk was downgraded to underweight by Morgan Stanley. Morgan Stanley analysts say a trial to test whether Novo Nordisk's blockbuster weight-loss drug also will work against Alzheimer's is ...

Eli Lilly's tirzepatide, marketed under the brands Mounjaro for diabetes and Zepbound for weight management, is highly ...

MANHATTAN — Kansas State football went into the week needing to show something that could instill confidence heading into the remainder of the season. It didn’t happen. Instead, the Wildcats are ...

Eli Lilly said in August that around 50 percent of employers had chosen to cover its weight-loss drug, Zepbound, little changed from a year earlier. Novo Nordisk said last month that about 40 million ...

WASHINGTON (AP) — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial ...